Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
May 03 2023 - 9:15AM
Sanara
MedTech Inc. (“Sanara,” the “Company,”
“we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company
focused on developing and commercializing transformative
technologies to improve clinical outcomes and reduce healthcare
expenditures in the surgical, chronic wound and skincare markets,
announced today details for the release of its results for the
quarter ended March 31, 2023.
Sanara will issue its earnings release on
Monday, May 15, 2023, and will host a conference call on Tuesday,
May 16, 2023, at 9:00 a.m. Eastern Time. The toll-free number to
call for this teleconference is 888-506-0062 (international
callers: 973-528-0011) and the access code is 728630. A telephonic
replay of the conference call will be available through Tuesday,
May 30, 2023, by dialing 877-481-4010 (international callers:
919-882-2331) and entering the replay passcode: 48363.
A live webcast of Sanara’s conference call will
be available under the Investor Relations section of the Company's
website, www.SanaraMedTech.com. A one-year online replay will be
available after the conclusion of the live broadcast.
About Sanara
MedTech Inc.
With a focus on improving patient outcomes
through evidence-based healing solutions, Sanara MedTech Inc.
markets, distributes and develops surgical, wound and skincare
products for use by physicians and clinicians in hospitals, clinics
and all post-acute care settings and offers wound care and
dermatology virtual consultation services via telemedicine.
Sanara’s products are primarily sold in the North American advanced
wound care and surgical tissue repair markets. Sanara markets and
distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG®
Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as
well as a portfolio of advanced biologic products focusing on
AMPLIFY™ Verified Inductive Bone Matrix, ALLOCYTE® Advanced
Cellular Bone Matrix, BiFORM® Bioactive Moldable Matrix and
TEXAGEN® Amniotic Membrane Allograft to the surgical market. In
addition, the following products are sold in the wound care market:
BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS™
Antimicrobial Wound Gel, BIAKŌS® Antimicrobial Skin and Wound
Irrigation Solution and HYCOL® Hydrolyzed Collagen. Sanara’s
pipeline also contains potentially transformative product
candidates for mitigation of opportunistic pathogens and biofilm,
wound re-epithelialization and closure, necrotic tissue
debridement, and cell compatible substrates. The Company believes
it has the ability to drive its pipeline from concept to
preclinical and clinical development while meeting quality and
regulatory requirements. Sanara is constantly seeking long-term
strategic partnerships with a focus on products that improve
outcomes at a lower overall cost. In addition, Sanara is actively
seeking to expand within its six focus areas of wound and skin care
for the acute, post-acute, and surgical markets. The focus areas
are debridement, biofilm removal, hydrolyzed collagen, advanced
biologics, negative pressure wound therapy products, and the oxygen
delivery system segment of the wound and skin care market.
Information about Forward-Looking
Statements
The statements in this press release that do not
constitute historical facts are “forward-looking statements,”
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by terms such as “aim,” “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,”
“forecast,” “guidance,” “intend,” “may,” “plan,” “possible,”
“potential,” “predicts,” “preliminary,” “project,” “seek,”
“should,” “target,” “will,” or “would,” or the negatives of these
terms, variations of these terms or other similar expressions.
These forward-looking statements include, among others, statements
regarding our business strategy and mission, the development of new
products, the regulatory approval process and expansion of the
Company’s business in telehealth and wound care. These items
involve risks, contingencies and uncertainties such as
uncertainties associated with the development and process for
obtaining regulatory approval for new products, the extent of
product demand, market and customer acceptance, the effect of
economic conditions, competition, pricing, the ability to
consummate and integrate acquisitions, and other risks,
contingencies and uncertainties detailed in the Company’s SEC
filings, which could cause the Company’s actual operating results,
performance or business plans or prospects to differ materially
from those expressed in, or implied by these statements.
All forward-looking statements speak only as of
the date on which they are made, and the Company undertakes no
obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events, except as
required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor
Relations713-826-0524CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
Sanara MedTech (NASDAQ:SMTI)
Historical Stock Chart
From Apr 2024 to May 2024
Sanara MedTech (NASDAQ:SMTI)
Historical Stock Chart
From May 2023 to May 2024